

Located in Washington DC, part of the School of Public Health





Forum for Gollaborative HIV Research



MEETING OBJECTIVES

Nina Mani PhD MPH Forum for Collaborative HIV Research





- Approval of the two direct acting antivirals (DAAs) is a therapeutic boon for those suffering from chronic hepatitis C viral infection
- Approved DAA + Pegylated interferon/Ribavirin
- Certain patients in particular populations such as those in the historical cohort of bleeding disorder patients
- Complications of long-standing liver disease and interferon intolerance
- Interferon-free DAA combinations



MEETING OBJECTIVES

- Identification of possible DAA combinations that could be used in this population: Risks and benefits
- Discussion of strategies that could facilitate access, if indicated, to interferon-free DAA combinations: Studies, treatment INDs
- Possible structural and logistical barriers, and ethical concerns: Study sites; outcome reporting; clinical specialties; grants



MEETING FORMAT

- Formal presentations in Session 1
- Followed by moderated discussion :
 - Discussion of questions posed by moderators



Forum for Gollaborative HIV Research



OPEN DISCUSSION

Kenneth Sherman MD, PhD University of Cincinnati College of Medicine

Veronica Miller PhD Forum for Collaborative HIV Research



MEETING OBJECTIVES

- Define inclusion/exclusion criteria for the population Investigational DAAs:
 - DAA characteristics for combination regimens
 - Drug-drug interaction studies
- Types of studies; Reporting requirements;
 - Clinical specialties needed for these trials
- When to start a treatment IND?
 - Where to conduct these trials: HTCs, ACTG, others?
- Other issues: Reimbursement for treating bleeding episodes during combination trials



Located in Washington DC, part of the School of Public Health

